Naples-Based Clinic Expands Into Telehealth Weight Loss with Provider-Reviewed GLP-1 Programs

NAPLES, Fla. — Eden Med Spa, an established clinical practice in Naples, Florida, has expanded its services into the telehealth space with the launch of EdenRx — a provider-reviewed platform offering medically supervised GLP-1 weight loss programs to patients in Florida and New York.

The platform offers compound semaglutide and compound tirzepatide programs under a model the company describes as "assessment-first" — requiring licensed provider approval before any payment is collected from prospective patients. This structural approach contrasts with many direct-to-consumer telehealth platforms that collect payment information before a clinical review has been completed.

A Clinical Practice at Its Core

EdenRx's origin in an existing in-person medical practice is central to how the company positions itself in an increasingly crowded telehealth weight loss market. Eden Med Spa has been serving patients in Naples for years, providing treatment across aesthetic medicine, wellness, and now — through EdenRx — telehealth-based GLP-1 programs.

"We built EdenRx from real clinical experience, not market research," the company stated in its launch communications. "Every process decision reflects how we actually treat patients — with provider review first and patient outcomes as the priority."

The EdenRx model requires all prospective patients to complete a medical questionnaire that is individually reviewed by a licensed provider in Florida or New York. The provider determines clinical appropriateness before any treatment plan is issued. No payment is required until after provider approval, and only if the patient chooses to proceed.

GLP-1 Programs Available

The platform currently offers compound semaglutide and compound tirzepatide programs at several pricing tiers. Compound medications dispensed through EdenRx are not FDA-approved under the same New Drug Application as brand-name equivalents such as Ozempic, Wegovy, Mounjaro, or Zepbound — a disclosure the company includes prominently in its patient-facing materials.

GLP-1 receptor agonists — including semaglutide and tirzepatide — have attracted significant attention following landmark clinical trials demonstrating substantial average weight loss in trial participants. The STEP 1 trial (semaglutide) reported approximately 15% mean body weight reduction at 68 weeks; the SURMOUNT-1 trial (tirzepatide) reported up to approximately 22% at 72 weeks. Both figures represent group averages from randomized controlled trials and do not predict individual outcomes.

Service Area and Availability

EdenRx is currently available to patients residing in Florida and New York — the states in which its providers are licensed. The company has stated it does not serve patients in other states, reflecting a compliance posture that limits service to jurisdictions where its clinical team holds active licensure.

Medication is dispensed through a licensed U.S. compound pharmacy and shipped directly to the patient's address. The platform includes a patient portal with secure messaging, monthly check-in forms, refill management, and order tracking.

Broader Market Context

The launch comes during a period of significant activity in the telehealth weight loss space. Several large platforms have entered the GLP-1 market following the high-profile success of brand-name medications. Regulatory bodies have also increased scrutiny of compound GLP-1 practices, making the clinical oversight model that EdenRx has built more relevant as a differentiator.

EdenRx does not make weight loss guarantees in its patient-facing materials — a deliberate choice the company attributes to clinical integrity rather than regulatory compliance alone. "Results vary by individual. A provider evaluates each case. We don't make promises we can't keep," the company noted.

About EdenRx

EdenRx is a provider-reviewed telehealth platform offering GLP-1 weight loss programs in Florida and New York. Built from Eden Med Spa in Naples, Florida, the platform operates under a licensed-provider-first model. For more information, visit tryedenrx.org.